Treating cancer when pRb and p53 cannot be reactivated

Activation of oncoproteins and inactivation of tumor suppressors induces tumorigenesis. When these events happen upstream of pRb and p53, cancer therapies may initially succeed and then fail when pRb and p53 are activated and then re-inactivated. Therapies might succeed if they remain effective when...

Descripción completa

Detalles Bibliográficos
Autor principal: Zhu, Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2015
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905341/
https://www.ncbi.nlm.nih.gov/pubmed/27308498
http://dx.doi.org/10.1080/23723556.2015.1004954
_version_ 1782437250461597696
author Zhu, Liang
author_facet Zhu, Liang
author_sort Zhu, Liang
collection PubMed
description Activation of oncoproteins and inactivation of tumor suppressors induces tumorigenesis. When these events happen upstream of pRb and p53, cancer therapies may initially succeed and then fail when pRb and p53 are activated and then re-inactivated. Therapies might succeed if they remain effective when pRb and p53 are genetically inactivated.
format Online
Article
Text
id pubmed-4905341
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-49053412016-06-15 Treating cancer when pRb and p53 cannot be reactivated Zhu, Liang Mol Cell Oncol Author's View Activation of oncoproteins and inactivation of tumor suppressors induces tumorigenesis. When these events happen upstream of pRb and p53, cancer therapies may initially succeed and then fail when pRb and p53 are activated and then re-inactivated. Therapies might succeed if they remain effective when pRb and p53 are genetically inactivated. Taylor & Francis 2015-05-05 /pmc/articles/PMC4905341/ /pubmed/27308498 http://dx.doi.org/10.1080/23723556.2015.1004954 Text en © 2015 The Author(s). Published with license by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.
spellingShingle Author's View
Zhu, Liang
Treating cancer when pRb and p53 cannot be reactivated
title Treating cancer when pRb and p53 cannot be reactivated
title_full Treating cancer when pRb and p53 cannot be reactivated
title_fullStr Treating cancer when pRb and p53 cannot be reactivated
title_full_unstemmed Treating cancer when pRb and p53 cannot be reactivated
title_short Treating cancer when pRb and p53 cannot be reactivated
title_sort treating cancer when prb and p53 cannot be reactivated
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905341/
https://www.ncbi.nlm.nih.gov/pubmed/27308498
http://dx.doi.org/10.1080/23723556.2015.1004954
work_keys_str_mv AT zhuliang treatingcancerwhenprbandp53cannotbereactivated

Ejemplares similares